Key Highlights

  • Net loss per share was USD 0.06 against an estimate of a USD 0.09 loss.
  • Net loss was USD 5.54 million, compared with USD 5.58 million.
  • Research and development expense was USD 4.38 million, compared with USD 1.68 million.
  • Cash, cash equivalents and investments were USD 36.49 million at September 30, 2026.

Rein Therapeutics (NASDAQ:RNTX) reported a net loss of USD 5.54 million for the third quarter of 2026, compared with USD 5.58 million in the third quarter of 2025. The net loss per share was USD 0.06, compared with USD 0.21, against an estimate of a USD 0.09 loss.

The company reported no Revenue in either period.

Operating Expenses

Research and development expense was USD 4.38 million, compared with USD 1.68 million, and general and administrative expense was USD 2.62 million, compared with USD 3.81 million. Total operating expenses, which equal the loss from operations, were USD 7.00 million, compared with USD 5.49 million.

Other income, net, was USD 1.46 million, compared with other expense, net, of USD 0.09 million. The filing states that the quarter included a USD 1.1 million gain from the Revaluation of 2026 Warrant liabilities, which were reclassified to Equity in July 2026.

Nine-Month Results

For the nine months ended September 30, 2026, the net loss was USD 17.75 million, compared with USD 17.90 million, and the net loss per share was USD 0.29, compared with USD 0.74. Research and Development expense was USD 11.09 million, compared with USD 9.03 million, and general and administrative expense was USD 7.22 million, compared with USD 8.94 million. Total operating expenses were USD 18.31 million, compared with USD 17.97 million.

Balance Sheet and Liquidity

Cash and cash equivalents were USD 0.94 million at September 30, 2026, compared with USD 3.22 million at December 31, 2025, and short-term investments were USD 34.55 million. Total Assets were USD 59.43 million, compared with USD 24.16 million. Management believes that cash, cash equivalents and investments of USD 36.49 million are sufficient to fund planned Operating Expense and Capital Expenditure requirements into the first quarter of 2028.

In May 2026, the company completed an underwritten public offering of 57,500,000 shares of common stock at a public offering price of USD 1.00 per share.

The company describes itself as a clinical stage biopharmaceutical company focused on novel therapies for fibrosis indications. Its lead product candidate, LTI-03, is being developed for the treatment of idiopathic pulmonary fibrosis and has completed Phase 1a and Phase 1b clinical trials. The company is conducting the Phase 2 RENEW trial, a multi-center, randomized, double-blind, placebo-controlled study. It initiated patient screening in May 2025, received regulatory clearances in Europe and the United Kingdom, and dosed its first patient in March 2026.

Weighted average common shares outstanding were 88,325,917 for the quarter, compared with 26,361,386. The company had 86,267,032 shares of common stock outstanding at September 30, 2026, compared with 27,550,222 at December 31, 2025. Goodwill was USD 6.33 million, intangible assets were USD 13.50 million, and the accumulated Deficit was USD 419.02 million, compared with USD 401.27 million.

Rein Therapeutics Q3 2026 Earnings: Key Takeaways

Rein Therapeutics reported a third quarter 2026 net loss of USD 5.54 million and a loss per share of USD 0.06. Cash, cash equivalents and investments were USD 36.49 million at September 30, 2026.